PharmaLists

06/28/2022

CDC Backs Moderna Vaccine for Those Aged 6 to 17

Learn more -> https://www.empr.com/home/news/cdc-backs-moderna-vaccine-for-those-aged-6-to-17/

06/07/2022

Heart Failure Hospitalization Risk Compared With Empagliflozin vs Other Glucose-Lowering Txs

Learn more -> https://www.empr.com/home/news/heart-failure-hospitalization-risk-compared-with-empagliflozin-vs-other-glucose-lowering-txs/

The EMPRISE study assessed the efficacy and safety of empagliflozin use in approximately 500,000 adults with type 2 diabetes.

05/20/2022

Gabapentin-Involved Overdose Deaths Increased Between 2019 and 2020

Learn more -> https://www.empr.com/home/news/gabapentin-involved-overdose-deaths-increased-between-2019-and-2020/

Researchers used data from the State Unintentional Drug Overdose Reporting System in order to assess trends in gabapentin-involved overdose deaths.

04/29/2022

Camzyos Approved for Obstructive Hypertrophic Cardiomyopathy

Learn more -> https://www.empr.com/home/news/camzyos-approved-for-obstructive-hypertrophic-cardiomyopathy/

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin.

04/22/2022

Adverse Effects Generally Mild After BNT162b2 mRNA Booster in Over 60s

Learn more -> https://www.empr.com/home/news/adverse-effects-generally-mild-after-bnt162b2-mrna-booster-in-over-60s/

04/14/2022

Pentosan Polysulfate Sodium SC Injection Fast Tracked for Osteoarthritis

Learn more -> https://www.empr.com/home/news/drugs-in-the-pipeline/pentosan-polysulfate-sodium-sc-injection-fast-tracked-for-osteoarthritis/

04/06/2022

Fetal Exposure to Cannabis Linked to Adiposity in Childhood

Learn more -> https://www.empr.com/home/news/fetal-exposure-to-cannabis-linked-to-adiposity-in-childhood/

03/30/2022

PreHevbrio Now Available for Adult Hepatitis B Vaccination

Learn more ->

03/25/2022

Nitrosamine Impurity Detected in Certain Lots of Orphenadrine Citrate ER Tablets

Learn more -> https://www.empr.com/home/news/safety-alerts-and-recalls/nitrosamine-impurity-detected-in-certain-lots-of-orphenadrine-citrate-er-tablets/

Orphenadrine citrate ER tablet is indicated as an adjunct to rest, physical therapy and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.

03/23/2022

FDA Accepts Resubmitted Teplizumab BLA for T1D Delay

Learn more -> https://www.empr.com/home/news/drugs-in-the-pipeline/fda-accepts-resubmitted-teplizumab-bla-for-t1d-delay/

Teplizumab is an investigational anti-CD3 monoclonal antibody that has been shown to preserve beta cell function, reducing the need for exogenous insulin.

03/18/2022

Gene Therapy for Canavan Disease Receives Multiple FDA Designations

Learn more -> https://www.empr.com/home/news/drugs-in-the-pipeline/gene-therapy-for-canavan-disease-receives-multiple-fda-designations/

The gene therapy candidate is designed to deliver the ASPA gene directly to the oligodendrocyte cells in the fluid surrounding the brain and spinal cord.

03/16/2022

The Big Sneeze: Climate Change to Make Pollen Season Nastier
Climate scientists at the University of Michigan looked at 15 different plant pollens and used computer simulations to calculate how much worse allergy season will likely get by the year 2100.

Learn more -> https://www.medscape.com/viewarticle/970405

03/12/2022

Mindfulness Intervention Cuts Opioid Misuse, Chronic Pain

Learn more -> https://www.empr.com/home/news/mindfulness-intervention-cuts-opioid-misuse-chronic-pain/

Additional benefits include reductions in opioid dosing, emotional distress, and opioid craving

03/09/2022

Community Genetic Testing Prompts Behavior Change in Patients
Test results for kidney failure risk prompt positive behavior change in patients and providers that might offset risk of developing chronic kidney disease and end-stage renal failure later in life.

Learn more -> https://www.medscape.com/viewarticle/969945

03/03/2022

Biosimilar Releuko Gets FDA Approval

Learn more -> https://www.empr.com/home/news/biosimilar-releuko-gets-fda-approval/

Approval was based on data demonstrating similarity between the 2 the biosimilar and reference product, Neupogen.

02/23/2022

Poor Trial Representation Tied to Worse Breast Cancer Survival
More than half of patients with early breast cancer are not well represented in clinical trials yet are receiving therapies based on results of these trials.

Learn more -> https://www.medscape.com/viewarticle/968979

02/17/2022

Pembrolizumab Plus Lenvatinib Not Superior to Pembrolizumab Alone in Advanced Urothelial Carcinoma

Learn more -> https://www.empr.com/home/mpr-first-report/asco-gu-2022/pembrolizumab-plus-lenvatinib-not-superior-to-pembrolizumab-alone-in-advanced-urothelial-carcinoma/

02/11/2022

Proposed Insurance Policy Ignites Debate Over Transgender Care

Learn more -> https://www.medscape.com/viewarticle/968321?src=